Cargando…

Correction: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515444/ https://www.ncbi.nlm.nih.gov/pubmed/34645674 http://dx.doi.org/10.1136/jitc-2020-001564corr1

Ejemplares similares

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Fukuda, Shohei, et al.
Publicado: (2021)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Sznol, Mario, et al.
Publicado: (2015)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
por: Brown, Landon C., et al.
Publicado: (2021)

Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
por: Matsumura, Soichi, et al.
Publicado: (2023)

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
por: Zahoor, Haris, et al.
Publicado: (2018)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Publicado: (2020)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
por: Catalano, Martina, et al.
Publicado: (2023)

Correction: A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient
por: De Bondt, Charlotte, et al.
Publicado: (2020)

Correction: The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma
por: Pagès, Gilles
Publicado: (2018)

Correction: Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
Publicado: (2023)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Analysis of Spatial Heterogeneity of Responses in Metastatic Sites in Renal Cell Carcinoma Patients Treated with Nivolumab
por: Jajodia, Ankush, et al.
Publicado: (2022)

Remission of ulcerative colitis flare-up induced by nivolumab
por: Iwamoto, Maho, et al.
Publicado: (2020)

Nivolumab/tozinameran: Flare-up of psoriasis: case report
Publicado: (2021)

Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma
por: Osawa, Takahiro, et al.
Publicado: (2020)

Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
por: Tanoue, Kenro, et al.
Publicado: (2021)

Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
por: Shields, Lisa B.E., et al.
Publicado: (2021)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2023)

Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2023)

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment
por: Meerveld-Eggink, Aafke, et al.
Publicado: (2022)

Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines
por: Gil, Lucia, et al.
Publicado: (2022)

Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Publicado: (2021)

Correction to: Heme oxygenase-1 deficiency presenting with interstitial lung disease and hemophagocytic flares
por: Chau, Alice S., et al.
Publicado: (2022)

C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
por: Nishio, Makoto, et al.
Publicado: (2023)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Nakajima, Nobuyuki, et al.
Publicado: (2020)

Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
por: Segawa, Takuya, et al.
Publicado: (2023)

Nivolumab–ipilimumab in renal cell carcinoma metastatic to the bones: A case report
por: Di Napoli, Marilena, et al.
Publicado: (2022)

Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
por: Teishima, Jun, et al.
Publicado: (2023)

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature
por: Saade, Anastasia, et al.
Publicado: (2019)

Author Correction: Towards an arthritis flare-responsive drug delivery system
por: Joshi, Nitin, et al.
Publicado: (2018)

Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Sazuka, Tomokazu, et al.
Publicado: (2021)

Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience
por: Bimbatti, Davide, et al.
Publicado: (2022)

A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab
por: Bazzi, Talal, et al.
Publicado: (2022)

Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab
por: Shao, Ning, et al.
Publicado: (2019)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sr1hmhpj2cshea834tgcd7bioj